Find Funding Opportunities

The purpose of this notice is to inform applicants of a change to the Key Dates for PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)". An additional receipt date has been added to this FOA.

The purpose of this notice is to inform applicants of a change to the Key Dates for PAR-20-122 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)". An additional receipt date has been added to this FOA.

The purpose of this notice is to correct an error in PAR-21-056 which incorrectly states that "Foreign components, as defined in the NIH Grants Policy Statement, are not allowed." As this should be corrected to reflect that Foreign components are allowed. This aligns with the companion PARs which all allow foreign components.

The purpose of this notice is to inform the community of the early termination of RFA-NS-21-015 "HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)" and it's reissuance as RFA-NS-22-052

The purpose of this notice is to extend the response date for NOT-NS-22-044 "BRAIN Initiative: Request for Information (RFI) on Industry Collaboration in Development and Dissemination of Non-Invasive Brain Imaging Technologies".

There is an urgent need for more research to establish best practices in the pain management field, however, there is a limited workforce pipeline of pain researchers to meet NIHs long-term goals of providing effective non-opioid options for the treatment of pain conditions and better pain management overall. The Interagency Pain Research Coordinating Committee (IPRCC) has identified the workforce problem as a barrier for new pain research, and has identified factors that contributed to it such as barriers to entry into the field of pain research that have constricted growth high departure rate of senior investigators and mentors. The IPRCC also identified a need for more structured opportunities for early-stage investigators to learn from and be mentored by experienced investigators. The pain management field has further recognized that basic, translational, and clinical researchers do not regularly collaborate when developing grant applications. If pain management researchers across all disciplines were to work together, it would enhance the innovation, relevance, and practical application of pain management research.To support the NIH HEAL Initiatives response supporting new investigators, promoting multidisciplinary collaborations among pain researchers, and identifying innovate treatments to manage pain, this FOA invites applications for the Coordinating Center for National Pain Scientists (CCNPS). The CCNPS will be a central facilitator for integrating training and mentoring across a network of mentors and early-stage investigators funded by NIH (e.g., NIH trainees, NIH fellows, and Career Development Awardees). The main purpose of the CCNPS is to enhance the training experience of new pain researchers across the continuum of basic, translational, and clinical research and create a vast network of NIH-funded pain researchers to promote multidisciplinary collaborations in pain research. The CCNPS will create and run a coordination center to connect NIH-fund

The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD),intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.

This Notice reflects the participation of multiple other NIH Offices, Institutes and Centers (OICs) in the NIH Science Education Partnership Awards (PAR-20-153). The SEPA program supports Pre-K to grade 12 (P-12) and informal science education (ISE) activities that: (1) enhance the diversity of the biomedical, behavioral and clinical research workforce and (2) foster a better understanding of NIH-funded biomedical, behavioral and clinical research and its public health implications. The SEPA program targets two primary audiences: (1) SEPA formal or classroom-based projects that provide STEM content, pedagogical expertise, and problem solving skills to teachers, students, and families in communities not generally supported by advanced and innovative educational practices: (2) SEPA informal science education (ISE) activities that are conducted in outside-the-classroom venues as well as in science centers and museums, target both workforce diversity and improved public health literacy.

The purpose of this notice is to rescind NOT-NS-22-053 "Notice of Special Interest (NOSI): Pain-Focused Administrative Supplements for NINDS Grants that are Not Focused on Pain Research". Due to budgetary constraints in FY22, it has become necessary to rescind this notice.

This Notice announces the participation of additional NIH Institutes and Centers in the NIH Science Education Partnership Awards (PAR-20-153). The SEPA program supports P-12 and informal science education (ISE) activities that: (1) enhance the diversity of the biomedical, behavioral and clinical research workforce and (2) foster a better understanding of NIH-funded biomedical, behavioral and clinical research and its public health implications. The SEPA program targets two primary audiences: (1) SEPA formal or classroom-based projects that provide STEM content, pedagogical expertise, and problem solving skills to teachers, students, and families in communities not generally supported by advanced and innovative educational practices: (2) SEPA informal science education (ISE) activities that are conducted in outside-the-classroom venues as well as in science centers and museums, target both workforce diversity and improved public health literacy. Applications that target pre-kindergarten to grade 12 (P-12) or ISE topics that cannot be addressed by existing school, community, or ISE-based activities are encouraged.